N¹-(tert-butyl)-2-aminoacetamide hydrochloride | 71034-40-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N¹-(tert-butyl)-2-aminoacetamide hydrochloride
• 英文别名: 2-amino-N-isobutylacetamide hydrochloride；glycine N-t-butylamide hydrochloride；2-amino-N-tert-butylacetamide;hydrochloride
• CAS: 71034-40-7
• 化学式: C₆H₁₄N₂O*ClH
• 分子量: 166.651
• InChiKey: WMOBCDULVRSMQL-UHFFFAOYSA-N

物化性质

• 沸点：
  259.3±23.0 °C(Predicted)
• 密度：
  0.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.28
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.1
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  N¹-(tert-butyl)-2-aminoacetamide hydrochloride 、 p-fluorophenyl 3-(p-methoxyphenyl)-2-propenyl ketone 在 吡啶 、 copper diacetate 作用下， 反应 3.0h， 以43%的产率得到5-(4-fluorophenyl)-N-isobutyl-3-(4-methoxyphenyl)-1H-pyrrole-2-carboxamide
  参考文献：
  名称：

  One-Pot Synthesis of Pyrrole-2-carboxylates and -carboxamides via an Electrocyclization/Oxidation Sequence

  摘要：

  An electrocyclic ring closure is the key step of an efficient one-pot method for the synthesis of pyrrole-2-carboxylates and -carboxamides from chalcones and glycine esters or amides. The 3,4-dihydro-2H-pyrrole intermediates generated in situ are oxidized to the corresponding pyrroles by stoichiometric oxidants or by catalytic copper(II) and air in moderate to high yields. A wide range of functional groups are tolerated, and further combination with an in situ bromination gives access to polyfunctional pyrrole scaffolds.

  DOI：

  10.1021/jo5021823
• 作为产物：
  描述：

  N-α-(tert-butoxycarbonyl)glycin-tert-butylamide 在 盐酸 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 20.0h， 以3.7 g的产率得到N¹-(tert-butyl)-2-aminoacetamide hydrochloride
  参考文献：
  名称：

  通过超分子互锁诱导动态催化剂中的对映选择性

  摘要：

  据报道，一类新型的以氨基酸为基础的双酰胺相互作用位点修饰的助熔联苯双亚膦酸酯（BIBIPHOS）配体的设计经历了自发的去对称作用。使用Rh-BIBIPHOS氢化前手性烯烃的对映体比例高达96：4（R / S）。通量BIBIPHOS配体的这种立体收敛行为是由识别位点的明显分子间互锁触发的，导致形成超分子组装体，其中联苯配体主链的轴向方向由氨基酸部分的手性支配。催化过程中的立体诱导与该过程解耦，并且由于配体的出现行为而直接产生。该超分子系统非常坚固，在对映选择性催化中具有被其他配体设计采用的潜力。

  DOI：

  10.1002/anie.201901175

文献信息

• N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl) oxyalkylamides and related compounds
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0254327A2

  公开（公告）日：1988-01-27

  Pharmaceutical compositions comprising, or compositions consisting essentially of, compounds according to the formula or an optical isomer thereof wherein Z is oxygen or NR²; n is an integer of 1 to 6; R¹ and R² are independently hydrogen; alkyl of 1 to 12 carbon atoms; cycloalkyl of 3 to 12 carbon atoms; hydroxalkyl of 1 to 6 carbon atoms; cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is optionally substituted with a lower alkyl, lower alkoxy, -OH, -OCOR³, halo, -N(R³)₂, -NHCOR³, -COOH, or -COOR³ group wherein R³ is lower alkyl; and phenyl or phenyl lower alkyl wherein phenyl is optionally substituted with at least one lower alkyl, halo or lower alkoxy group or an -N(R³)₂, -NHCOR³, -COOH, or -COOR³ group wherein R³ is lower alkyl; or R¹ and R² are combined with the N to which they are attached to form a cyclic secondary amine radical having from 5 to 8 atoms, where, in addition to the N atom, the atoms in the radical comprise carbon atoms and can include one oxygen or sulfur atom, or one optionally lower alkyl substituted nitrogen atom; HX is optionally present and when present represents the acid portion of a pharmaceutically acceptable acid additional salt; A is NR⁴R⁵ wherein R⁴ and R⁵ are independently selected from the group consisting of: hydrogen; alkyl of 1 to 6 carbon atoms; hydroxyalkyl of 2 to 6 carbon atoms; cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is optionally substituted with a lower alkyl, lower alkoxy, -OH, -OCOR³, halo, -N(R³)₂, -NHCOR³, -COOH, or -COOR³ group wherein R³ is lower alkyl; and phenyl or phenyl lower alkyl wherein phenyl is optionally substituted with at least one lower alkyl, halo or lower alkoxy group or an -N(R³)₂, -NHCOR³, -COOH, or -COOR³ group wherein R³ is lower alkyl; or wherein R⁴ and R⁵ are combined to form a compound selected from the group consisting of: morpholinyl, piperidinyl, perhexylenyl, N-loweralkylpiperazinyl, pyrrolidinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, (±)-decahydroquinolinyl and indolinyl. The invention is also directed to certain compounds of the above class. The compounds of Formula I are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents and the like in mammals.

  药物组合物，包含或主要包含如下式的化合物 或其光学异构体 其中 Z 是氧或 NR² n 是 1 至 6 的整数； R¹ 和 R² 独立地为氢；1 至 12 个碳原子的烷基；3 至 12 个碳原子的环烷基；1 至 6 个碳原子的羟烷基；4 至 12 个碳原子的环烷基低级烷基，其中环烷基环任选被低级烷基、低级烷氧基、-OH、-OCOR³、卤代、-N(R³)₂、-NHCOR³、-COOH 或 -COOR³ 基团取代，其中 R³ 为低级烷基；苯基或苯基低级烷基，其中苯基可选择被至少一个低级烷基、卤代或低级烷氧基或-N(R³)₂、-NHCOR³、-COOH 或-COOR³基团取代，其中 R³ 为低级烷基；或 R¹ 和 R² 与它们所连接的 N 结合，形成具有 5 至 8 个原子的环状仲胺基，其中，除 N 原子外，基中的原子包括碳原子，还可包括一个氧原子或硫原子，或一个任选被低级烷基取代的氮原子； HX 可任选存在，存在时代表药学上可接受的酸附加盐的酸部分； A 是 NR⁴R⁵，其中 R⁴ 和 R⁵ 独立选自由以下组成的组：氢；1 至 6 个碳原子的烷基；2 至 6 个碳原子的羟烷基；3 至 8 个碳原子的环烷基或 4 至 12 个碳原子的环烷基低级烷基，其中环烷基环任选被低级烷基、低级烷氧基、-OH、-OCOR³、卤代、-N(R³)₂、-NHCOR³、-COOH 或 -COOR³ 基团取代，其中 R³ 为低级烷基；苯基或苯基低级烷基，其中苯基任选被至少一个低级烷基、卤代或低级烷氧基或-N(R³)₂、-NHCOR³、-COOH 或-COOR³基团取代，其中 R³ 为低级烷基；或其中 R⁴ 和 R⁵ 结合形成选自由以下组成的化合物：吗啉基、哌啶基、过己烯基、N-低烷基哌嗪基、吡咯烷基、四氢喹啉基、四氢异喹啉基、(±)-十氢喹啉基和吲哚啉基。本发明还涉及上述类别中的某些化合物。式 I 的化合物是环 AMP 磷酸二酯酶抑制剂，可用作哺乳动物的抗血栓和肌力促进剂等。
• The structure-activity profile of mercaptobenzamides’ anti-HIV activity suggests that thermodynamics of metabolism is more important than binding affinity to the target
  作者：Herman Nikolayevskiy、Marco Robello、Michael T. Scerba、Evan H. Pasternak、Mrinmoy Saha、Tracy L. Hartman、Caitlin A. Buchholz、Robert W. Buckheit、Stewart R. Durell、Daniel H. Appella

  DOI：10.1016/j.ejmech.2019.06.020

  日期：2019.9

  Mercaptobenzamide thioesters and thioethers are chemically simple HIV-1 maturation inhibitors with a unique mechanism of action, low toxicity, and a high barrier to viral resistance. A structure-activity relationship (SAR) profile based on 39 mercaptobenzamide prodrug analogs exposed divergent activity/toxicity roles for the internal and terminal amides. To probe the relationship between antiviral activity and toxicity, we generated an improved computational model for the binding of mercaptobenzamide thioesters (SAMTs) to the HIV-1 NCp7 C-terminal zinc finger, revealing the presence of a second low-energy binding orientation, hitherto undisclosed. Finally, using NMR-derived thiol -thioester exchange equilibrium constants, we propose that thermodynamics plays a role in determining the antiviral activity observed in the SAR profile. (C) 2019 Published by Elsevier Masson SAS.
• Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo
  作者：Chu-Biao Xue、Matthew E. Voss、David J. Nelson、James J.-W. Duan、Robert J. Cherney、Irina C. Jacobson、Xiaohua He、John Roderick、Lihua Chen、Ronald L. Corbett、Li Wang、Dayton T. Meyer、Kenneth Kennedy、William F. DeGrado、Karl D. Hardman、Christopher A. Teleha、Bruce D. Jaffee、Rui-Qin Liu、Robert A. Copeland、Maryanne B. Covington、David D. Christ、James M. Trzaskos、Robert C. Newton、Ronald L. Magolda、Ruth R. Wexler、Carl P. Decicco

  DOI：10.1021/jm010127e

  日期：2001.8.1

  To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the PI and P2 ' residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1-P2 ' linkers. With an N-methylamide at P3 ', the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-alpha release from LPS-stimulated human whole blood. Further elaboration in the P3 ' -P4 ' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of less than or equal to 0.2 muM in whole blood assay (WBA). Although the P3 ' area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3 ' was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3 ', an N-methylamide at P4 ' provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 muM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4 ' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC50 = 0.067 muM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K-i values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.
• Phase transfer catalyzed asymmetric alkylations of imine glycinamides
  作者：Sanjeev Kumar、Uma Ramachandran

  DOI：10.1016/s0957-4166(03)00441-5

  日期：2003.9

  Herein we report the use of achiral imine glycinamides as substrates for asymmetric alkylations using chiral phase-transfer catalysts for the first time. Initially tried for obtaining a key intermediate for the synthesis of levobupivacaine, we expanded the study to other N-mono and N,N-disubstituted imine glycinamides. A possible explanation for the lower enantioselectivity observed in the ease of alkylation of N-monosubstituted as compared to N,N-disubstituted glycinamides is also provided. (C) 2003 Elsevier Ltd. All rights reserved.
• LETTIERI, G.;BRANCACCIO, G.;LARIZZA, A., BOLL. CHIM. FARM., 1981, 120, N 5, 308-310
  作者：LETTIERI, G.、BRANCACCIO, G.、LARIZZA, A.

  DOI：——

  日期：——